In bladder cancer, data from the CheckMate-275 and IMvigor210 trials demonstrated that patients with ARID1A mutations and high CXCL13 expression had favorable outcomes following ICI treatment (33). The gene discussed is CXCL13; the disease is urinary bladder carcinoma.